Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
As of Mar. 2026, Hikari Heights-Varus Co has a Sloan Ratio of -1.24%, indicating the company is in the safe zone and there is no funny business with accruals.
Hikari Heights-Varus Co (SSE:2137) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Mar. 2026, Hikari Heights-Varus Co has a Sloan Ratio of -1.24%, indicating the company is in the safe zone and there is no funny business with accruals.
Hikari Heights-Varus Co Sloan Ratio % Related Terms
Hikari Heights-Varus Co Sloan Ratio % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SSE:2137 vs HCA, THC, EHC: Sloan Ratio % Comparison
For the Medical Care Facilities subindustry, Hikari Heights-Varus Co's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hikari Heights-Varus Co Sloan Ratio % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Hikari Heights-Varus Co's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Hikari Heights-Varus Co's Sloan Ratio % falls into.
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Hikari Heights-Varus Co's Sloan Ratio for the fiscal year that ended in Mar. 2026 is calculated as
For company reported semi-annually, GuruFocus uses latest two semi-annual data as the TTM data.
Hikari Heights-Varus Co's Net Income for the trailing twelve months (TTM) ended in Mar. 2026 was -215.461 (Sep. 2025 ) + -100.236 (Mar. 2026 ) = 円-316 Mil.
Hikari Heights-Varus Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was -124.047 (Sep. 2025 ) + -150.008 (Mar. 2026 ) = 円-274 Mil.
Hikari Heights-Varus Co's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2026 was 27.82 (Sep. 2025 ) + 17.702 (Mar. 2026 ) = 円46 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hikari Heights-Varus Co (SSE:2137) has a Sloan Ratio % of -1.24% as of Mar. 2026. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Hikari Heights-Varus Co and its competitors.
Is Hikari Heights-Varus Co's Sloan Ratio % too high?
Hikari Heights-Varus Co's current Sloan Ratio % is -1.24%. Overall, Hikari Heights-Varus Co has a GF Score™ of 50/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Hikari Heights-Varus Co's Sloan Ratio % compare to HCA and THC?
Hikari Heights-Varus Co's Sloan Ratio % of -1.24% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Sloan Ratio % for a Healthcare Providers & Services company?
A good Sloan Ratio % depends on the Healthcare Providers & Services industry context. However, Sloan Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Sloan Ratio % mean?
A high Sloan Ratio % can signal that a stock is expensive relative to its fundamentals. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Hikari Heights-Varus Co and its competitors. Hikari Heights-Varus Co's current Sloan Ratio % is -1.24%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hikari Heights-Varus Co stock overvalued right now?
Based on GuruFocus' analysis, Hikari Heights-Varus Co (SSE:2137) is currently considered Fairly Valued. The stock's GF Value™ is 円730.18, compared to a current price of 円720.00 — trading 1.4% below its estimated fair value. The current Sloan Ratio % is -1.24%. Hikari Heights-Varus Co's overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Sloan Ratio % calculated?
Sloan Ratio % is calculated from a company's financial statements. For Hikari Heights-Varus Co (SSE:2137), the current Sloan Ratio % is -1.24% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hikari Heights-Varus Co (SSE:2137) Overvalued in 2026?
Based on GuruFocus' analysis, Hikari Heights-Varus Co stock appears to be undervalued.
The current stock price of 円720.00 is trading 1.4% below its estimated GF Value™ of 円730.18.
GuruFocus considers Hikari Heights-Varus Co to be Fairly Valued.
Key valuation signals for SSE:2137:
Sloan Ratio %: -1.24%
GF Value™: 円730.18 vs. price of 円720.00 (1.4% below fair value)
No single metric tells the full story. See the SSE:2137 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hikari Heights-Varus Co Ltd is a Japanese firm engaged in operating senior homes. It operates nursing homes for the elderly. The company provides rooms for healthy elderly as well as ones requiring assisted living.
50GF Score
Get the complete analysis for SSE:2137
Sloan Ratio % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SSE:2137 has been successfully added to your 
